News
According to a media release by AstraZeneca on April 28, 2022,
WILMINGTON, Del., April 28, 2022 – ULTOMIRIS® (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.
Here is a link to the media release for more information Click HERE for Link
A Research Opportunity is now available for individuals with Myasthenia Gravis.
HealthPartners is recruiting people to examine the effect of acupuncture treatment on the quality of life and the activities of daily living in people with MG
There is no cost to participate. For more information call 651-495-6323 or email ClinicalTrials@HealthPartners.com
Brochures with additional information are linked below
The U.S. Food and Drug Administration on December 17 approved Vyvgart (efgartigimod) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.
Click HERE to access the press release for more information.
Please ask your doctor is this therapy is right for you.
We are sad to report that Owen Johnson passed away December 4th. He was an active member of our support group and reqularly attended our Zoom sessions. His wife, MaryAnn told us that he was diagnosed with MG in 2019 but his cause of death was other health issues.
Here is a link to his obituary.
https://www.legacy.com/us/obituaries/twincities/name/owen-johnson-obituary?id=31845909
Dear MG Minnesota Conference Attendees,
Thank you for attending the fifth annual conference this past Sunday. It was wonderful to see your faces and listen to your questions.
At the bottom of this post are the documents that David Hughes, the physical therapist mentioned.
Here are the links to David’s and Josh’s presentations. Please feel free to share the link with people you think would be interested in these videos. They are NOT on YouTube. Please do not make them available for the entire world to view. If you would like to re-listen to Dr. Guliani’s quick presentation, please send me a note and I will send you the link, when I receive permission from him.
David Hughes, physical therapist
Josh Frederickson, “Living Better with MG” https://us02web.zoom.us/rec/share/3fJhvYWW2NQ5wirS_sghAO8gmI2FggwcLd04igLE40sOjUuG_4VpdSjPMet9aGPq.WbjO6xhCwVGyvLIt?startTime=1632668222000
Again, thank you for attending the conference. We hope to see you in 2022.
The 2021 Annual Meeting held on September 26th was very informative. We had a presentation about how to do low impact exercises by David Hughes of Big Stone Therapy. Josh Fredrickson talked to us about how to live better with MG. Dr. Gaurav Guliani from HealthPartners/Park Nicollet gave us updates from the medical world. Dr Guliani is also our Chief Medical Advisor for mgMN.
The Board of Directors gave their annual reports.
Thank you to all our attendees for a very good and informative meeting.
We are sad to report the passing of Lianne Anderson
She had MG since 1975. She began serving on the MGFA Minnesota Chapter Board of Directors in the late 1970’s and chaired the Twin Cities Support Group since its inception. She also served as Chair of Fundraising with efforts to bring in a sustainable amount for the chapter and for the newly formed mgMN organization. Lianne and her mother Millie established The Anderson Fund in honor of her late father Irv. The Anderson Fund is an active account within mgMN and is used to support the mission of Myasthenia Gravis Minnesota.
Her obituary is linked below and asks for donations to the mgMN Anderson Fund. If you wish to honor Lianne with a donation to our organization, please send a check made out to Myasthenia Gravis Minnesota and put Anderson Fund in the comments. Send a check to:
Monica St. Gernain (mgMN Treasurer)
16511 Lake Ridge Drive
Maple Grove, MN 55311
Harbour BioMed‘s HBM9161 was found to be safe and effective at reducing the levels of autoimmune disease-associated antibodies in many disorders, including myasthenia gravis, a Phase 1 trial shows. In autoimmune diseases such as myasthenia gravis, a type of antibody known as immunoglobulin G (IgG) attacks the body’s own cells and tissues, breaking down normal communication between……
The National Institutes of Health (NIH) has awarded $7.8 million for the launch of a rare disease network, called MGNet, to drive research in myasthenia gravis and which will be led by experts from George Washington University, Yale University, and Duke University.
Ra Pharmaceuticals is preparing to launch a Phase 3 clinical trial to assess the therapeutic potential of zilucoplan for the treatment of patients with generalized myasthenia gravis (gMG). This comes after the company’s completion of End-of-Phase 2 interactions with the FDA
Note: Medical information included on this website comes from sources that are noted along with the information. Citing a source on this website does not imply an endorsement by Myasthenia Gravis Minnesota, Inc. (mgMN). Always consult your physician, pharmacist, nurse or other health care professional for advice and expertise regarding the care that is best for you.
